The AspirinWorks® Test was developed in conjunction with strategic partners Creative Clinical Concepts (CCC), a Denver-based biotechnology company, and Cayman Chemical Company (Cayman), an Ann Arbor, Mich. manufacturer of biochemical research products. The test measures the biomarker of thromboxane, the chemical that makes platelets sticky, and which Aspirin affects.
Although we can’t measure thromboxane directly, we can easily and non-invasively measure 11-dehydro thromboxane B2, its chemical biomarker, using the AspirinWorks Test in urine. Other tests require freshly drawn blood that must be evaluated within four hours, but the AspirinWorks Test only requires a urine sample that can be obtained in any doctor’s office or patient service center. In fact, the AspirinWorks Test is the only FDA-cleared test that accurately determines aspirin effect by measuring levels of this biomarker in urine.
A low level of the biomarker in the urine means that aspirin is working to reduce thromboxane production. High levels of the biomarker may mean that your dosage of aspirin is not effective for decreasing the risk of a heart attack or stroke, and it’s time for you and your doctor to consider increasing the dose or changing your treatment strategy.
If you are not sure that the aspirin you are taking is working, it’s time to ask your doctor about the AspirinWorks Test.